Page last updated: 2024-10-25

ciprofibrate and Insulin Resistance

ciprofibrate has been researched along with Insulin Resistance in 1 studies

Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.

Research Excerpts

ExcerptRelevanceReference
" The objective of this study was to determine whether treatment with the peroxisome proliferator-activated receptor-α (PPARα) agonist ciprofibrate has direct effects on cardiac and hepatic metabolism and can improve insulin sensitivity and cardiac function in insulin-resistant volunteers."5.69The tissue-specific metabolic effects of the PPARα agonist ciprofibrate in insulin-resistant male individuals: a double-blind, randomized, placebo-controlled crossover study. ( de Wit-Verheggen, VHW; Gemmink, A; Haas, J; Hesselink, MKC; Joris, PJ; Liénard, V; Montaigne, D; Nascimento, EBM; Phielix, E; Raiko, J; Schaart, G; Schrauwen, P; Schrauwen-Hinderling, VB; Staels, B; van de Weijer, T; Vanweert, F; Wierts, R; Wildberger, JE, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
de Wit-Verheggen, VHW1
Vanweert, F1
Raiko, J1
Liénard, V1
Schaart, G1
Gemmink, A1
Nascimento, EBM1
Hesselink, MKC1
Wildberger, JE1
Wierts, R1
Joris, PJ1
Haas, J1
Montaigne, D1
Staels, B1
Phielix, E1
Schrauwen, P1
Schrauwen-Hinderling, VB1
van de Weijer, T1

Trials

1 trial available for ciprofibrate and Insulin Resistance

ArticleYear
The tissue-specific metabolic effects of the PPARα agonist ciprofibrate in insulin-resistant male individuals: a double-blind, randomized, placebo-controlled crossover study.
    Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:10

    Topics: Cross-Over Studies; Fluorodeoxyglucose F18; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance

2023